Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2016

View Archived Issues

First preclinical data demonstrate mutant EGFR selectivity of new inhibitor

Novel antibody mixture inhibits tumor growth in MET-amplified models

Bayer Pharma presents preclinical data for the novel anti-TweakR antibody, BAY-356

Pfizer presents highlights of first quarter 2016

Ohr Pharmaceutical develops biodegradable microparticle AMD treatment OHR-3031

Stevia First to become Vitality Biopharma with focus on cannabinoid prodrugs

Cynata Therapeutics and apceth enter license option agreement

Aptinyx completes series A financing

Interim data from Avelas' phase Ib trial of AVB-620 surgical marker

Verona Pharma announces positive phase II results for RPL-554 in patients with COPD

WAVE advances exon 51 DMD candidate and extends research collaboration with University of Oxford

Galapagos initiates phase I trial of its potentiator compound GLPG-2451

CJ CheilJedang reports compounds to treat constipation

Vitae Pharmaceuticals discloses RORgamma inverse agonists

Dermira discloses phase II results for DRM-01

Ferrer to acquire Alexza Pharmaceuticals

Achaogen enters antibody collaboration with Crystal Bioscience

Iron chelator Apo-6856 improves memory in Alzheimer's disease model

Sun Pharma Advanced Research initiates phase I/II study of K-0706

MacroGenics and Pfizer announce first patient dosed with PF-0661008

Janssen plans phase IIb study of AL-335, odalasvir and simeprevir combinations for chronic HCV

FDA grants fast track status to KemPharm's KP-511

New pilot study explores use of ARA-290 for diabetic macular edema

US Phytotherapy conducting preclinical studies of PROACT-Z for Zika infection

Treating Leber's congenital amaurosis type 10 with RNA antisense oligonucleotide QR-110

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 3, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 3, 2025.
Researchers arm CAR T cells to fight solid tumors
BioWorld
Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
Bioversys, Shionogi in CHF529M lung infection collaboration
BioWorld Science
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...
Medtronic receives CE mark for its Vitalflow ECMO system
BioWorld MedTech
Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...